228 related articles for article (PubMed ID: 35445839)
1. The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study.
Bloomfield MAP; Yamamori Y; Hindocha C; Jones APM; Yim JLL; Walker HR; Statton B; Wall MB; Lees RH; Howes OD; Curran VH; Roiser JP; Freeman TP
Psychopharmacology (Berl); 2022 May; 239(5):1539-1549. PubMed ID: 35445839
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
[TBL] [Abstract][Full Text] [Related]
3. The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial.
Gournay LR; Ferretti ML; Bilsky S; Vance E; Nguyen AM; Mann E; Williams P; Leen-Feldner EW
Psychopharmacology (Berl); 2023 Oct; 240(10):2147-2161. PubMed ID: 37552290
[TBL] [Abstract][Full Text] [Related]
4. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
5. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Crippa JA; Derenusson GN; Ferrari TB; Wichert-Ana L; Duran FL; Martin-Santos R; Simões MV; Bhattacharyya S; Fusar-Poli P; Atakan Z; Santos Filho A; Freitas-Ferrari MC; McGuire PK; Zuardi AW; Busatto GF; Hallak JE
J Psychopharmacol; 2011 Jan; 25(1):121-30. PubMed ID: 20829306
[TBL] [Abstract][Full Text] [Related]
6. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study.
Spinella TC; Stewart SH; Naugler J; Yakovenko I; Barrett SP
Psychopharmacology (Berl); 2021 Jul; 238(7):1965-1977. PubMed ID: 33813611
[TBL] [Abstract][Full Text] [Related]
7. A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of Cannabidiol on Experiences of Test Anxiety Among College Students.
Stanley TB; Ferretti ML; Bonn-Miller MO; Irons JG
Cannabis Cannabinoid Res; 2023 Dec; 8(6):1090-1099. PubMed ID: 35861792
[No Abstract] [Full Text] [Related]
8. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Bergamaschi MM; Queiroz RH; Chagas MH; de Oliveira DC; De Martinis BS; Kapczinski F; Quevedo J; Roesler R; Schröder N; Nardi AE; Martín-Santos R; Hallak JE; Zuardi AW; Crippa JA
Neuropsychopharmacology; 2011 May; 36(6):1219-26. PubMed ID: 21307846
[TBL] [Abstract][Full Text] [Related]
9. Effects of cannabidiol (CBD) on regional cerebral blood flow.
Crippa JA; Zuardi AW; Garrido GE; Wichert-Ana L; Guarnieri R; Ferrari L; Azevedo-Marques PM; Hallak JE; McGuire PK; Filho Busatto G
Neuropsychopharmacology; 2004 Feb; 29(2):417-26. PubMed ID: 14583744
[TBL] [Abstract][Full Text] [Related]
10. Effect of prior foot shock stress and Δ
Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.
Gundugurti PR; Banda N; Yadlapalli SSR; Narala A; Thatikonda R; Kocherlakota C; Kothapalli KS
Asian J Psychiatr; 2024 Jul; 97():104073. PubMed ID: 38797087
[TBL] [Abstract][Full Text] [Related]
12. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
Appiah-Kusi E; Petros N; Wilson R; Colizzi M; Bossong MG; Valmaggia L; Mondelli V; McGuire P; Bhattacharyya S
Psychopharmacology (Berl); 2020 Apr; 237(4):1121-1130. PubMed ID: 31915861
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
[TBL] [Abstract][Full Text] [Related]
14. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.
Bhattacharyya S; Wilson R; Appiah-Kusi E; O'Neill A; Brammer M; Perez J; Murray R; Allen P; Bossong MG; McGuire P
JAMA Psychiatry; 2018 Nov; 75(11):1107-1117. PubMed ID: 30167644
[TBL] [Abstract][Full Text] [Related]
15. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis.
Davies C; Wilson R; Appiah-Kusi E; Blest-Hopley G; Brammer M; Perez J; Murray RM; Allen P; Bossong MG; McGuire P; Bhattacharyya S
Transl Psychiatry; 2020 Sep; 10(1):311. PubMed ID: 32921794
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
de Faria SM; de Morais Fabrício D; Tumas V; Castro PC; Ponti MA; Hallak JE; Zuardi AW; Crippa JAS; Chagas MHN
J Psychopharmacol; 2020 Feb; 34(2):189-196. PubMed ID: 31909680
[TBL] [Abstract][Full Text] [Related]
17. The impact of cannabidiol placebo on responses to an acute stressor: A replication and proof of concept study.
Zhekova RM; Perry RN; Spinella TC; Dockrill K; Stewart SH; Barrett SP
J Psychopharmacol; 2024 Jan; 38(1):116-124. PubMed ID: 38214314
[TBL] [Abstract][Full Text] [Related]
18. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder.
Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
Psychopharmacology (Berl); 2022 May; 239(5):1499-1507. PubMed ID: 35029706
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis.
Gunasekera B; Wilson R; O'Neill A; Blest-Hopley G; O'Daly O; Bhattacharyya S
Psychol Med; 2023 Jul; 53(10):4732-4741. PubMed ID: 35775365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
